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Abstract
Background: The equine infection anemia virus (EIAV) p9 Gag protein contains the late (L-)
domain required for efficient virus release of nascent virions from the cell membrane of infected
cell.
Results: In the present study the p9 protein and N- and C-terminal fragments (residues 1-21 and
22-51, respectively) were chemically synthesized and used for structural analyses. Circular
dichroism and 1H-NMR spectroscopy provide the first molecular insight into the secondary
structure and folding of this 51-amino acid protein under different solution conditions. Qualitative
1H-chemical shift and NOE data indicate that in a pure aqueous environment p9 favors an
unstructured state. In its most structured state under hydrophobic conditions, p9 adopts a stable
helical structure within the C-terminus. Quantitative NOE data further revealed that this α-helix
extends from Ser-27 to Ser-48, while the N-terminal residues remain unstructured. The structural
elements identified for p9 differ substantially from that of the functional homologous HIV-1 p6
protein.
Conclusions: These structural differences are discussed in the context of the different types of L-
domains regulating distinct cellular pathways in virus budding. EIAV p9 mediates virus release by
recruiting the ALG2-interacting protein X (ALIX) via the YPDL-motif to the site of virus budding,
the counterpart of the YPXnL-motif found in p6. However, p6 contains an additional PTAP L-
domain that promotes HIV-1 release by binding to the tumor susceptibility gene 101 (Tsg101). The
notion that structures found in p9 differ form that of p6 further support the idea that different
mechanisms regulate binding of ALIX to primary versus secondary L-domains types.
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Background
Equine infectious anemia virus (EIAV) is a retrovirus of
the lentivirus subfamily which also includes HIV-1, HIV-2
and simian immunodeficiency viruses (SIVs). Compared
to the primate lentiviruses the EIAV genome is the small-
est (~8.2 kb) and genetically simplest as it contains only
three accessory genes (rev, tat, and S2) in addition to the
canonical retroviral elements gag, pol, and env. As with
other retroviruses the Gag polyprotein Pr55 of EIAV is
required and sufficient for assembly and budding of virus
like particles. The cleavage of the Pr55 Gag-precursor by
the virus-encoded protease thereby yields the four major
internal structural proteins: the matrix (MA, p15), capsid
(CA, p26), nucleocapsid (NC, p11), and p9 proteins [1,2].
The Gag proteins are synthesized in the cytoplasm and tar-
geted to the plasma membrane where they assemble into
immature budding particles that consist predominantly of
uncleaved polyproteins and are released from the cell
membrane [3]. Maturation of the EIAV particle occurs
concurrently with or shortly after release of the progeny
virion in concert with protease activation.
The genomic position of p9 is analogous to that of the
HIV-1 p6 protein and other similar proteins from differ-
ent lentiviruses. Compared to HIV-1 p6, EIAV p9 has only
minimal amino acid sequence homology and a consider-
able variation in the predicted secondary structure.
Besides the function of p9 in viral DNA production and
processing of the provirus [4], p9 plays, like p6 of HIV-1,
an essential role in virus release, which are governed by
late assembly domains (L-domains). Proline-rich L-
domains, such as PTAP and PPPY have been identified in
HIV-1, Rous sarcoma virus (RSV), and a variety of other
enveloped viruses [5-7]. The HIV-1 PTAP motif specifi-
cally interacts with the N-terminus of the tumor suscepti-
bility gene 101 (Tsg101), a component of the host
endosomal sorting complex required for transport I
(ESCRT I), a system that regulates membrane fission dur-
ing multivesicular body (MVB) formation and cytokinesis
[8-12]. Interestingly, the EIAV YPDL L-domain motif has
been shown to interact with two cellular proteins, the
ALG-2-interacting-protein-X (ALIX/AIP1; ALIX is used
hereafter) [7,10] and the μ2 subunit of the AP-2 adaptor
protein complex [13].
Although L-domains appear to interact with different cel-
lular proteins, a certain functional interchangeability has
been reported. For example, both PTAP and PPPY motifs
can substitute for the YPDL domain to support EIAV rep-
lication [14]. These observations indicate that retrovi-
ruses, along with other enveloped viruses, have evolved
different L-domains to specifically exploit certain host cel-
lular machineries for virus budding and release.
Recently, we have characterized the structure of the HIV-1
p6 protein [15], and others have studied the structure of
p6 fragments in complex with binding partners Tsg101
and ALIX [16,17]. Among known lentiviruses, the 51-
amino acid EIAV p9 protein is one of the smallest proteins
and the molecular structure has not been defined hith-
erto. With the goal of understanding the molecular mech-
anism involved in the biological function of p9, we have
explored the high resolution structure and folding of p9,
derived from the EIAVWYOMING isolate, under various solu-
tion conditions. Although the molecule exhibits a high
degree of flexibility in a pure aqueous environment it
adopts α-helical structures in an hydrophobic environ-
ment simulated by organic solvents. According to high
resolution NMR data, p9 consists of two independent
structural domains, an unstructured N-terminus and an
extended C-terminal helix. The structure of p9 was com-
pared with that of HIV-1 p6, and their similarities and dif-
ferences are discussed in terms of differences in their L-
domain functions.
Results
Synthesis and purification of synthetic p9 (sp9)
An overview of the previously reported binding domains
for ALIX and AP-2 within the EIAV p9 protein and their
relationship to the primary structure derived from the
EIAVWYOMING sequence, together with the predicted sites
of post-translational modification, are shown in Fig. 1.
The sp9 molecule (sp91-51) and its fragments (sp91-21 and
sp922-51) were chemically synthesized using solid-phase
peptide synthesis (SPPS) and purified to homogeneity.
The specific procedure, established previously by us for
the HIV-1 p6 protein [15] with respect to the use of cou-
pling agents, protection groups, cleavage reagents, and
duration of coupling reactions, gave reproducibly high
yields (usually 15%) of purified sp91-51. It avoided prob-
lems normally encountered in such syntheses that include
incomplete deprotection and coupling, inter- and intra-
chain reaction with the resin matrix, side chain reactions,
and peptide aggregation.
We also synthesized N- and C-terminal fragments of p9
using the same SPPS protocol. After cleavage from the
resin, the crude peptides were purified. Illustrative data
are shown in Additional file 1 for the full-length peptide
sp91-51  and the N- and C-terminal fragments thereof
(Additional file 1, Fig. S1-3). The purity of sp91-51 and its
related fragment peptides was confirmed by molecular
mass determination using positive ion electrospray ioni-
zation mass spectrometry (ESI-MS). The experimental
results for sp91-51 showed a well defined multiply charged
spectrum showing 7-4-fold positively charged ions (Fig.
2A) that was deconvoluted to give an intense envelope for
the molecular ion cluster [M+H]+ centered at a molecular
mass of 6053.9 Da (Fig. 2B), corresponding to a calcu-
lated molecular weight of 6055.6 Da. This was confirmed
by MALDI-MS (data not shown). Similarly, the N- and C-BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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Molecular characteristics of p9 Figure 1
Molecular characteristics of p9. Primary amino acid sequence of the p9 protein is shown. Predicted phosphorylation sites, 
positions of positively and negatively charged side chains, sites for covalent attachment of ubiquitin (Ub) as well as the known 
binding domain for ALIX and AP-2 are indicated. Sequence positions of the synthetic peptides sp9 1-51, sp91-21, and sp922-51 are 
shown at the bottom of the figure.
Mass spectrum of sp91-51 Figure 2
Mass spectrum of sp91-51. A. Experimental mass spectrum of p91-51 showing the distribution of multiply charged ions, [M + 
7H]7+, [M + 6H]6+, [M + 5H]5+, [M + 4H]4+. B. Deconvoluted mass spectrum showing the envelope of the molecular ion cen-
tred at 6053.9.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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terminal fragments of p9 also afforded high quality data
and the correct molecular masses (Additional file 1). The
cumulative HPLC and MS data indicated sp91-51 and its
fragments showed very little evidence of by-products and
were pure enough (> 95%) for biophysical studies.
Predicted structural details of EIAV p9
Several in-silico prediction programs have been employed
to derive secondary structure information from the p9 pri-
mary sequence (EIAVWYOMING). All predictions converge
to indicate that p9 is largely an unstructured molecule that
has only a small propensity for helical structure (Table 1).
The predicted helix is located in the C-terminal region,
while the N-terminus of the molecule contains very little
secondary structure if any. However, all the prediction
algorithms indicate the C-terminal region has at least 7-
residues in an α-helical conformation located between
Leu-26 and Glu-32. A further short helix, approximately 5
residues in length, is centered on residue-42 (~residues
Gln-40 to Leu-44). Thus, the in silico analysis suggests the
existence of two C-terminal helices in p9.
C-terminus contributes to p9 secondary structure
A first insight into the secondary structure and folding of
sp91-51 and its fragments thereof was obtained by analysis
of the peptides at ambient temperature under various
solution conditions by circular dichroism (CD) spectros-
copy. We simulated a hydrophobic environment by using
the organic solvent trifluoroethanol (TFE) to assess the
degree of secondary structure under hydrophobic condi-
tions. TFE is chosen for its well known characteristics as it
favors intramolecular interactions and stabilizes second-
ary structure, particularly α-helices in domains of a pep-
tide that have a propensity for such secondary structure
[18]. As TFE tends to disrupt quaternary structure and dis-
sociate peptide aggregates, it can alleviate problems occur-
ring with intermolecular interactions in the higher
concentration ranges required for NMR investigations and
provide a platform to perform CD and NMR studies under
similar solution conditions.
The far-ultraviolet CD spectra of the full length molecule
and its fragments are shown in Fig. 3. The spectrum of
sp91-51 shows a strong ellipticity minimum at 196 nm
with a small shoulder near 216 nm under aqueous (pure
water, pH 3.0) conditions, which is characteristic of a ran-
dom coil conformation with very little evidence of sec-
ondary structure (Fig. 3A). Although a negative signal near
200 nm could be associated with disordered structure, the
broad nature of the band suggests the presence of some
structure. A similar spectrum was obtained when the mol-
ecule was analyzed at physiological pH (phosphate
buffer, pH 7.2). However, addition of 50% TFE (at pH 3),
affords two sharp signals at 208 nm and 222 nm and a
positive signal at ~189 nm, indicating establishment of an
α-helical structure under these hydrophobic conditions.
Yet, the full length molecule looses significant α-helical
content in 50% TFE at neutral pH (Fig. 3A). Thus, the CD
data suggest that sp91-51 adopts α-helical structure in the
presence of a hydrophobic environment under acidic con-
ditions that is less stable in neutral pH.
Two synthetic N- and C-terminal fragments were used to
locate the structured region of the molecule by comparing
the respective secondary structure contents. In 50% TFE
(pH 3.0) the N- and C-terminal fragments showed ca.
7.0% and 34.3% helical content, respectively, indicating
secondary structure is predominantly located in the C-ter-
minal section of the molecule (Fig. 3B and 3C) whereas
the N-terminal fragment sp91-21 showed no evidence of
secondary structure under any of the conditions used, sug-
gesting it is largely unstructured and does not contribute
to the secondary structure of the molecule. In contrast, the
C-terminal fragment exhibited folding behavior similar to
that of sp91-51 under the same solution conditions (Fig. 3C
and 3A). The percentage helical content calculated for the
C-terminal fragment of ~34%, using the DICROPOT 2000
program, corresponds to 10 amino acids which is in-line
with our observation for the full length molecule and con-
firms the C-terminus contains the locus for most of the
secondary structure in the molecule (Table 2).
Identification of structural elements in sp91-21, sp922-51, 
and sp91-51 by 1H NMR spectroscopy
In order to define in more detail the position of secondary
structure identified by CD spectroscopy, we have recorded
1H NMR spectra of full length sp91-51 and the N- and C-ter-
minal fragments sp91-21 and  sp922-51 dissolved in 50%
aqueous TFE-d2. Initially, we have analyzed the structural
characteristics of the peptides on the basis of 1Hα chemical
shift data, which correlate with the chemical environment
of the respective amino acid residues and therefore have
proven to be useful for determining the presence, nature
and exact position of secondary structure elements in such
molecules [19]. For instance, a minimum of four adjacent
residues, showing pronounced upfield shifts relative to
Table 1: Secondary structure prediction for p9 using public 
domain semi-empirical programs
Method α-helix 1 α-helix 2 Reference
Target99 26-33 [40]
SSpro 26-32 41-43 [41,42]
PORTER 26-33 [43]
PsiPred 26-33 (9-13) 41-42 [44]
PROF 26-32 36-39, 41-44 [45]
PHD 26-32 [46]
GOR I 25-51 (1-4) [47]
GOR IV 26-36 40-44 [48]
HNN 25-32 40-44 [49]
SOPMA 24-33 41-51 [50]
GOR V 27-44 [51,52]BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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random coil values (< -0.1 ppm) indicate local helical
structure while downfield shifts (> 0.1 ppm) of three or
more adjacent residues are indicative of α-helical struc-
tures. In order to obtain these data a set of one- and two-
dimensional (1D, 2D) 1H NMR spectra was recorded for
each peptide. Signal assignments of the NMR spectra were
accomplished using a standard procedure combining
homonuclear 2D TOCSY and 2D NOESY NMR spectral
data [20]. Individual spin systems were identified from
2D TOCSY spectra, starting from the backbone amide pro-
tons. Sequence-specific assignments were determined
from cross-peaks in the 2D NOESY spectra based on short
observable distances between 1HN, 1Hα and 1Hβ nuclei of
amino acid residue i and 1HN of residue i+1. Spin systems
that could readily be recognized were used as starting
points to establish residue positions in the peptide
sequence.
For each peptide the 1Hα chemical shift differences relative
to random coil values were determined and plotted
against the respective sequence (Fig. 4A, B, and 4C). It can
readily be seen that no substantial secondary structure is
present in the N-terminal portion of sp9 (Fig. 4A and 4C)
as no stretch of adjacent residues showing either upfield
or downfield shifts is present. The only pronounced
downfield shifts observed for Glu-15 and Thr-16 can be
explained by the presence of a proline residue in position
17. As demonstrated previously in the context of HIV-1
Vpr [21,22] proline residues generally cause unusual
intrinsic downfield shifts of 0.28 ppm ± 0.1 ppm in the
Far UV CD spectra of sp9 and fragments thereof Figure 3
Far UV CD spectra of sp9 and fragments thereof. Far UV CD spectra of sp91-51 (A), sp91-21 (B), and sp922-51 (C) 
recorded at different TFE concentrations and different pH values. (D) Summary of secondary structure content (% helix) under 
different solution conditions.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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preceding residues and of 0.08 ppm ± 0.03 ppm in resi-
dues two positions towards the N-terminus. Taking this
proline-effect into consideration clearly rationalizes the
downfield shifts of Glu-15 and Thr-16 and implies that
these residues are in an unstructured environment.
Unlike the N-terminus, the C-terminal region shows a
large number of upfield shifts comprising residues Ser-27
to Leu-49 and therefore is clearly indicative of the pres-
ence of helical structure in this section of the molecule
(Fig. 4B and 4C). Even though residues Glu-28 and Glu-
42 exhibit upfield shifts of only - 0.042 and - 0.079,
respectively, it seems most likely that they are both part of
a continuous helix, which in the case of Glu-28 becomes
evident by the presence of very pronounced upfield shifts
of the neighboring residues Ser-27 and Ile-29, and in the
case of Glu-42 by a further stretch of seven weakly helical
residues located directly to the C-terminal side of Glu-42.
However, as the upfield shifts of these residues (Glu-42/
Asp-43 to Leu-49) are distinctly less pronounced we
assume that this part of the helix possesses decreased sta-
bility. At its N-terminus the helix is delimited by Pro-24, a
residue that is often considered to be a helix-breaker.
A comparison of the 1Hα chemical shift differences of the
full length molecule with those of the two fragments
reveals that they are almost identical apart from residues
Leu-22 to Leu-26. This observation can easily be explained
with the fact that this site represents the interface of the
two fragments and therefore the respective C- (sp91-21) or
N-terminus (sp922-51) whereas it is the central region of
full length sp9.
It was possible to identify and quantify only a limited
number of unambiguous medium range NOEs in the 2D
NOESY spectrum of sp91-51 and these were insufficient to
calculate a meaningful structure. However, they could be
used to assess secondary structure in the full length mole-
cule. The interproton distances dNN(i, i+1) and dαN(i, i+1)
were determined and their ratios were used to calculate
the probabilities for secondary structures in short seg-
ments (dipeptides) of the sp91-51 molecule. In an ideal α-
helix dNN(i, i+1) is 2.8 Å and dαN(i, i+1) is 3.5 Å while an
extended strand shows distances of 4.3 Å for dNN(i, i+1)
and of 2.2 Å for dαN(i, i+1), respectively. Using the equa-
tion given by Bradley et al. [23] the combination of these
and the experimentally determined values of these dis-
tances allows an estimation of whether the respective
dipeptides are in a helical, extended or a more unordered
conformations. Fig. 5 shows the probability for particular
secondary structure against the sequence of sp9. Although
there was no full sequence coverage with the required sig-
nals from the NOESY spectrum it can readily be deduced
from the plot that no marked and well defined secondary
structure is present in the N-terminal section of the mole-
cule. Even though most dipeptides in the region Pro-1/Ile-
2 to Asn-21/Leu-22 show a weak propensity for helix for-
mation the merely moderate increase of values suggest a
more random rather than a stable helical conformation.
These change towards the C-terminus (Asp-25/Leu-26 to
Trp-50/Glu-51) where a large majority of the observed
distance combinations results in clearly increased values
thereby implying the presence of an α-helix in this region.
Structure calculations from quantitative NOE data
The problem observed above for the full length molecule
was caused by the overlap of signals that could therefore
not be unambiguously identified or accurately quantified
in the 2D spectra. Most likely, this problem arose from the
high proportion of similar amino acids in the p9 sequence
(Asn/Asp, Gln/Glu and Leu/Ile) that are distributed
throughout the molecule. As all the qualitative data indi-
cate the sole structured region in the molecule is restricted
to the C-terminal region we focused our attention on the
C-terminal peptide. This resolved the problem of signal
overlap and allowed identification of sufficient medium
range NOEs for structure calculations.
Hence after quantification of the NOE data a total of 346
NOEs (Fig. 6A and Table 2) were used as distance
restraints to calculate 100 structures using a standard pro-
tocol [24]. The 20 structures with the lowest NOE and
total energies and without distance violations greater than
0.2 Å were chosen for the final fitting analysis (Table 2).
The heterogeneity within these structures was assessed
using the consecutive segment approach, in which the
rmsd (root mean square deviations) of the backbone
atoms for short segments, 2-5 residues in length, were sys-
tematically and pair wise determined [25]. This analysis
allows identification of regions of high similarity within
the 20 final conformations and therefore identification of
Table 2: Structural statistics for the 20 final structures of sp922-51 
in 50% TFE
No. of distance constrains
Total 358
Intraresidual (|i-j| = 0) 113
Sequential (|i-j| = 1) 137
Medium range (|i-j| ≤ 4) 108




Evan der Walls 88.27
Ebond + Eangle + Eimpropers 167.1
Ramachandran plota
% residues with φ, ψ in most favourable regions 63
% residues with φ, ψ in additionally allowed regions 22.2
% residues with φ, ψ in generally allowed regions 14.8
% residues with φ, ψ in disallowed regions 0
a Only for central structureBMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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stable structural elements. The best defined regions of the
molecule were then those showing rmsd of the backbone
atoms of less than 0.2 Å, namely a continuous stretch
comprising amino acid residues Asp-25 to Glu-51 in
which the 20 refined structures share a high degree of sim-
ilarity (Fig. 6B). This finding is in good agreement with
the  1Hα  chemical shift data, the observed qualitative
NOEs, and the Bradley-analysis which all suggest the pres-
ence of a well defined α-helix in the region Ser-27 to Leu-
49.
A central structure, in terms of the position in 3D space,
was determined for the selected 20 lowest NOE and total
energy structures using LSQMAN and MOLMAN2 (Upp-
sala Factory Package [26]). The central structure was then
used as a template to superimpose and compare the other
19 refined low energy structures and the resulting set of
aligned conformations is shown in Fig. 6C. The central
structure is shown in Fig. 7 with a helical conformation
between residues Ser-27 and Leu-49.
Discussion
Secondary structure of p9 is strongly dependent upon 
solution conditions
Previous studies have established p9 as the functional
equivalent of the HIV-1 p6 protein, although these pro-
teins of almost identical size have only limited sequence
homology. Therefore, a comparison of the structural
Chemical shift differences of α-protons Figure 4
Chemical shift differences of α-protons. Chemical shift differences (ppm) of the α-protons between the experimental val-
ues and those for residues in a random coil for (A) sp91-21, (B) sp922-51 (B), and (C) sp91-51 in 50% TFE at 300 K.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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properties of these two analogous proteins is required to
understand their structure-function relationships and
their interactions with the same cellular factors such as
ALIX. In water, p6 adopts a random coil conformation
without any preference for secondary structure [15,27]
while in a hydrophobic environment specific regions, res-
idues 14-18 (helix 1) and residues 35-44 (helix 2), of the
molecule adopt helical structure [15]. Helix 2 of HIV-1 p6
appears to be important for specific binding interactions
with ALIX [16].
In the quest to establish the structural details of the EIAV
p9 molecule, CD analysis of sp91-51 shows that the mole-
cule has no significant or very little secondary structure
when dissolved in pure water at pH 3 or in buffer at phys-
iological pH 7.2. However, secondary structure is
observed and clearly stabilized in the presence of increas-
ing amounts (up to 50%) of TFE used to introduce a more
hydrophobic environment that is assumed to more
closely simulate in vivo conditions where p9 is exposed to
the hydrophobic surfaces of other proteins. However, for
sp91-51 maximum α-helical content was found at room
temperature in 50% aqueous TFE at pH 3 that decreased
upon changing the pH to 7.2, irrespective of the hydro-
phobic environment (Fig. 3A). The CD data for the N- and
C-terminal fragments clearly indicate secondary structure
formation in solution is restricted to the C-terminus of the
molecule. This fragment also behaves in a similar manner
to the full length molecule in that maximal structure is
found in 50% TFE and is less stable at physiological pH
(Fig. 3C).
As in our previous structural elucidation of HIV-1 p6 we
completely assigned the 1D and 2D 1H NMR spectra of
sp91-51, in conjunction with its N- and C-terminal frag-
ments, to afford the position and nature of structured
regions in the molecule. Well established criteria used pre-
viously by us, namely 1Hα chemical shifts, indicate in its
most structured state sp9 shows one region with a propen-
sity for α-helical structure in the C-terminal region of the
protein extending from Leu-26/Ile-28 to Ser-48. Accord-
ing to the chemical shift differences in both the full-length
sp9 and the shorter C-terminal peptide sp922-51 there is
some indication that the structured region extends back to
residue Leu-26. The smaller negative differences observed
towards the C-terminus indicate a weakening of the heli-
cal interactions in this region. A probability analysis for
helical or extended conformation of dipeptidic segments
for a limited number of interproton distances in the full
length molecule support this conclusion (Fig. 5). The C-
terminal fragment exhibited 34.3% helical content in
50% TFE. In contrast to the C-terminal peptide there was
no evidence of any structured region in the N-terminus
either in the full length molecule or its N-terminal pep-
tide. This was apparent even under the most favorable
conditions (50% TFE at pH 3) independently from both
the CD and NMR data.
Based on the above and the limited number of unambig-
uously assigned medium range NOEs caused by signal
overlap of similar amino acid spin systems in sp91-51,
structural calculations were undertaken of the C-terminal
fragment sp922-51, which contains the L-domain and the
only structured region of the molecule. The molecular
dynamic calculations, using a total of 358 quantitative
NOEs that included 137 sequential and 108 medium
range NOEs, afford a central arrangement that confines
the helical structure to the region between Glu-28 to Asp-
47 (Fig. 7).
Comparison of the structure of EIAV p9 and HIV-1 p6
A considerable amount of literature now exists suggesting
that EIAV p9 and HIV-1 p6 have several functions in com-
mon. Interestingly, these two functionally analogous pro-
teins possess quite different biochemical and biophysical
properties i.e. primary sequence, hydrophilicity and net
charge, which would be expected to lead to different pro-
tein-protein interactions in the respective host cell system.
Both proteins possess little sequence homology (only
~7% identity) and are predicted to differ significantly in
their phosphorylation propensities. HIV-1 p6 was charac-
terized as a largely phosphorylated protein [28]. Similarly,
both molecules have two ubiquitinylation sites and were
shown to become mono-ubiquitinylated, and in the case
of p6, sumoylated, Fig. 1[29-31].
Probabilities for helical, extended or random conformation in  sp9 calculated from the ratios of the interproton distances  dNN (i, i+1) and d N (i, i+1) in the respective dipeptidic seg- ments of sp1-51 in 50% TFE at 300 K Figure 5
Probabilities for helical, extended or random confor-
mation in sp9 calculated from the ratios of the inter-
proton distances dNN (i, i+1) and d N (i, i+1) in the 
respective dipeptidic segments of sp1-51 in 50% TFE at 
300 K.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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Summary of the observed NOEs for the C-terminus of sp9 Figure 6
Summary of the observed NOEs for the C-terminus of sp9. (A) Summary of the observed short and medium range 
NOEs for sp922-51 in 50% TFE at 300 K. (B) Root mean square deviations (rmsd) for the backbone atoms of sp922-51 in each res-
idue calculated using the consecutive segment method plotted against the residue number for the 20 final structures. (C) Sup-
position of the 20 best final restrained structures of sp922-51 after alignment of the backbone atoms of residues Ser-27 to Ser-
48. Shown are structures comprising residues Leu-22 to Glu-51.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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In their most structured states both molecules possess sta-
ble secondary structure although neither molecule pos-
sesses a stable tertiary structure. In a hydrophobic
environment at low pH, both adopt helical secondary
structure in their C-termini, although the helical region in
p9 is longer (22 residues) than that of p6 (12 residues)
under the same conditions. In each case the molecules are
highly flexible and, unlike most structured proteins, must
be considered as a dynamic equilibrium of many different
conformers that have the overall propensity for secondary
structure in the regions depicted in Fig. 8. Nevertheless, in
its most structured form, the p6 molecule adopts a helix-
turn-helix conformation in its C-terminal region whereas
p9 assumes a single continuous helical conformation. The
charge distribution within p6 and p9 is also distinctly dif-
ferent as the helix of p9 contains more charged residues
than p6 (Fig. 8). Such differences in this helical region will
be important for specific interactions with host cell factors
(see below).
The L-domains of p9 and p6, as well as similar domains
from other viral systems, have received considerable
attention as they play critical roles in controlling the inter-
action with the host system that finally promotes viral
budding and particle release [5-7]. These interactions
involve the binding of specific regions of each molecule
with components of the ESCRT [11,12]. Of particular rel-
evance is the well-defined interaction of both molecules
with ALIX, an ESCRT associated, multifunctional protein
that interacts with both ESCRT-I and ESCRT-III. The ALIX-
binding motif in both molecules responsible for this
interaction has been defined recently as (L) [FY]PX1-3LXX
[IL] [32-34] and corresponds in our case to 22LYPDLSEI in
p9 and 35LYPLASLRSL in p6 in which essential residues
are in bold. Recently, the structure of ALIX has been
worked out in detail [16,32,35] and its interaction with p6
was modeled based on NMR data of p6 [32]. In this
model the C-terminal helix found in hydrophobic envi-
ronments aligns coaxially with three helices in the ALIX V
domain long arm to form a four-helix bundle [16]. The
presence of a similar helical motif in the C-terminus of p9
presumably affords the same binding interaction. It is
important to note that the ALIX-binding domain of p6 is
located within the helical region of the molecule while in
p9 it is located in a partially unstructured region.
The structural investigations on p6 and p9 offer a ration-
ale for the different spacing of the essential residues in the
ALIX-binding domains pointed out by Munshi et al. [33].
During ALIX binding hydrophobic conditions pertain and
both molecules will adopt their most structured confor-
mations. In p9 the ALIX-binding domain 22LYPDL27SEI
motif is at the junction of an unstructured and beginning
of the helical region (Ser-27) of the molecule in this con-
formation (Fig. 7 and 8), while in p6 the whole
35LYPLASLRSL motif is found within the helical region
under the same conditions, Fig. 8[15]. In this helical con-
formation the essential lysine residue at position 42 in p6
is brought into the proximity of the 3 amino acid
sequence LYP through the introduction of one helix turn,
the intervening two residues are now on the opposite side
of the helix away from the hydrophobic interaction site of
the ALIX V domain [16]. This re-arranged recognition site
of adjacent residues 35LYP 40SLRSL now imitates the ALIX
motif LYPDLSEI of p9. Thus, the helical conformation in
p6 is required to position the essential residues correctly
and maintain the ALIX-p6 functional interaction by re-ori-
enting the 39LA residues to the other side of helix away
Final structure of sp922-51 in 50% TFE Figure 7
Final structure of sp922-51 in 50% TFE. (A) Central struc-
ture of sp922-51 that shows the lowest average rmsd value to 
all other final structures. (B) Ribbon plot of the same show-
ing helical regions. The boxed area corresponds to the posi-
tion of the ALIX-binding domain. (C) Space-filling 
representation of the central structure in the same orienta-
tion as in A. (D) Space-filling representation rotated 180°.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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from the interaction site, while this is not necessary for p9.
In addition, the C-terminal helix of p9 is substantially
longer than the corresponding helix in p6 (Fig. 8) and
thereby has a larger surface for potential interaction with
the ALIX V domain. These structural differences in the
ALIX-binding domains of the two molecules are reflected
in the considerably higher thermodynamic stability of the
p9-ALIX complexes [32,34] suggesting p9 has an opti-
mized ALIX-binding site compared to that of p6 [34].
Recently, the X-ray structures of the complexes of ALIX
with short synthetic peptides corresponding to the L-
domains of HIV-1 p6 and EIAV p9 have been elucidated
[34]. In these studies, the conserved tyrosine residue of
the L-domains plays a crucial role in positioning the pep-
tides in the same hydrophobic groove of arm 2 of the ALIX
V domain. In keeping with our analysis of the solution
structures an extra helical turn is observed in the crystal
structure of p6 to position Leu-42 in the same position as
Leu-26 in p9. These structures also define the orientation
of the peptide chains and indicate the ALIX V domain is
able to accommodate the short peptides without any
major helical movements between the free and bound
forms. According to our solution data the C-terminal hel-
ical region of both p6 and p9 could be accommodated
towards the open neck of the ALIX V domain [16] while
the flexible N-termini would allow these to be accommo-
dated in the loop region. It remains to be determined
whether these interactions of the full length proteins in
the context of the uncleaved Gag polyprotein cause
unfolding of ALIX.
Until recently the L-domains of p9 and p6 have usually
been defined as those regions containing the YPDL and
PT/SAP motifs, respectively [5-7]. Clearly this implies the
ALIX-binding domain and L-domain motifs overlap (or
are identical) in p9, but are separated in p6 where the L-
domain is positioned proximal to the PTAP motif, Fig. 8.
For p6, the PTAP L-domain binds to Tsg101, the human
equivalent of Vps23 of the yeast ESCRT-I complex that has
recently been completely defined structurally [35]. Cur-
rently, there is no evidence of an equivalent interaction for
p9. Indeed, the optimized ALIX binding site in p9 implies
EIAV requires only a single L-domain for budding while
the suboptimal binding site found in p6 requires the pres-
ence of a second site that functions through binding to
Tsg101. This is corroborated by sequence data for p6
derived from different SIV strains where those containing
high affinity ALIX binding sites do not have a Tsg101
binding site and vice versa [36].
Thus, it can be argued that the YPDL L-domain of EIAV
does not require an independent ESCRT-I interaction
[37,38] as the interactions between ESCRT-I and ESCRT-
III are bridged through an appropriate conformation of
ALIX stabilized by the strong interaction of p9. Presuma-
bly, in this bound form the N-terminal domain of ALIX
binds to the ESCRT-III complex while the C-terminal pro-
line-rich region binds the Tsg101 binding domain of
ESCRT-I.
In summary, p9 from EIAV, like p6 from HIV-1, is struc-
turally very labile and can exist in a number of conforma-
tional states that depend on its environment and the
presence of binding partners that interact with specific
domains in the molecule.
Conclusions
Although p9 and p6 are sequentially quite different, both
possess C-terminal helical structures in their most struc-
tured states that must be present during binding to the
hydrophobic pocket of ALIX, a central control node in
viral budding. Differences in the structural features in the
vicinity of the ALIX-binding motif correlate with the dif-
ferent binding properties of the molecules and with the
requirement of a further L-domain found only in p6 in the
weakly structured N-terminal domain.
Methods
Peptides and protein
The sequence of full length p9 and its two fragments, p91-
21 and p922-51, used in this study is that derived from the
isolate EIAVWYOMING, Fig. 1 (16).
Peptide synthesis, purification, and characterization
The syntheses of the full length peptide were performed
on an ABI 433A automated peptide synthesizer (Applied
Biosystems, Darmstadt, Germany) on a 0.1 mM scale with
300 mg TentaGel S-Trt-Glu(tBu)-Fmoc-resin (capacity
0.17 mmol/g; RAPP Polymere GmbH Tübingen, Ger-
many) using the Fmoc (N-(9-fluorenyl)methoxycarbo-
nyl)/t-butyl strategy. The following side-chain protecting
groups were used: t-butyloxycarbonyl (Trp, Lys), t-butyl
ether (Thr, Ser, Tyr), t-butyl ester (Asp, Glu) and trityl
(Asn, Gln and His). Couplings were performed with N-
[1H-7-aza-benzotriazol(1-yl)(dimethylamino)-methyl-
ene]-N-methylmethanaminium hexafluoro-phosphate-
N-oxide in N-methylpyrrolidone as coupling agent.
Amino acids in positions 10 and 11 (Lys-Ser) were intro-
duced as the pseudoproline derivative Fmoc-Lys(Boc)-
Ser(ΨMe, Me Pro)-OH. Deprotection of the Fmoc group was
performed during the complete synthesis with 20% pipe-
ridine in N,N-dimethylformamide. The final cleavage
from the resin was performed with 95% TFA in water con-
taining 3% triisopropylsilane and 5% phenol. The crude
protein was purified by reversed phase HPLC (RP-HPLC)
on a 7 μ Zorbax SB C18 column (21.2 × 250 mm) with a
linear gradient of 50% B to 60% B in 45 min (A: 2500 ml
water, 5 ml TFA; B: 2000 ml acetonitrile, 500 ml water, 5
ml TFA) at a flow rate of 10 ml/min with spectrophoto-
metric monitoring at λ = 220 nm. The fractions wereBMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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checked by RP-HPLC (Shimadzu LC10) on a Nulceosil C
18 column (4.6 × 125 mm, 5 μ, 300 Å) with a linear gra-
dient of 10% B to 100% B over 45 min to give the final
pure products. The fragments sp91-21 and  sp922-51 were
synthesized and purified in the same manner. The full
length synthetic protein and the N- and C-terminal pep-
tides are designated as sp9, sp91-21 and sp922-51, respec-
tively.
Peptide sequencing and mass spectrometry
For  sp9, the sequencing steps were completed on an
Applied Biosystems 473A pulsed liquid phase sequencer
according to a standard protocol. Positive ion ESI mass
spectra were recorded on a Micromass Q-Tof-2™ mass
spectrometer. Samples were dissolved in 70% aqueous
methanol and infused at a flow rate of ca. 1 μl/min at ca.
0.8 kv needle voltage into the electrospray chamber The
experimental spectra showing multiply charged molecular
ions were deconvoluted with standard software. MALDI/
TOF mass spectra were recorded on a Bruker reflex
MALDI/TOF mass spectrometer using an N2 laser (337
nm) (see additional file 1).
Circular dichroism (CD) spectroscopy
CD spectra of the protein samples of full-length sp9 and
its related shorter fragments sp91-21  and  sp922-51were
recorded at room temperature and a concentration of 0.2
mg ml-1 in 0.5 mm cuvettes on a Jasco J-810 spectropola-
rimeter in a wavelength range from 260 to 180 nm at var-
ious pH values and trifluoroethanol (TFE) concentrations
as described previously [15]. The resulting curves were
smoothed using a high frequency filter, and secondary
structure elements were quantified by deconvoluting the
measured ellipticity using the DICROPROT 2000 pro-
gram [39].
1H NMR spectroscopy
All one- (1D) and two-dimensional (2D) 1H NMR spectra
of sp9 and its fragments sp91-21 and sp922-51 were recorded
with (1D) or without (2D) spinning at 300 K on a Bruker
Avance DMX 600 MHz instrument using a triple reso-
nance probe head with gradient unit. The peptides were
dissolved without pH adjustment (pH ~3.0) to final con-
centrations of 2-3 mM in 1:1 mixtures of H2O and
CF3CD2OH (50% aqueous TFE-d2). Measurements were
carried out with mixing times of 110 ms for the 2D
TOCSY and 500 ms for the 2D NOESY experiments,
respectively. Data acquisition, processing and spectral
analysis were in all cases performed with standard Bruker
software. All spectra were internally referenced to the
residual TFE-H2 methylene signal at 3.95 ppm. The unam-
biguous amino acid spin systems and the sequential
assignments (see additional file 1) were established using
a standard procedure [15]. The complete signal assign-
ments and 1H chemical shifts of sp922-51 have been depos-
ited in the Biological Magnetic Resonance Data Bank
under accession number RCSB100795.
Structural calculations
The structure of sp922-51 was determined from quantitative
NOE data as described in detail elsewhere [15]. Structures
were calculated on a Silicon Graphics Octane work station
Schematic comparison of the Tsg101- and ALIX-binding domains of p6 and p9 in relation to the experimentally determined  secondary structures in 50% TFE Figure 8
Schematic comparison of the Tsg101- and ALIX-binding domains of p6 and p9 in relation to the experimen-
tally determined secondary structures in 50% TFE.BMC Structural Biology 2009, 9:74 http://www.biomedcentral.com/1472-6807/9/74
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using the program CNS 1.0 with standard CNS parameters
for protein data sets [24]. A total of 346 distance restraints
were used to generate 100 conformations of which 20
conformations, exhibiting no restraint violations greater
than 0.2 Å and having the lowest energy values, were used
for the final fitting analysis.
The heterogeneity within the final set of 20 structures was
visualized using the consecutive segment approach which
allows fitting regions for alignments to be defined (19).
The central structure showing the lowest root mean square
deviation (rmsd) of its fitting region to those of the other
structures was then determined using the programs LSQ-
MAN and MOLEMAN2 (Uppsala Software Factory) [26].
Finally, alignments were performed by superimposing the
fitting regions of all other structures to that of the central
structure and these were visualized with the PYMOL pro-
gram http://www.pymol.org. The final structure of sp922-
51 has been deposited in the Protein Data Bank under code
PDBID 2K84.
In this study the probability for helical or extended con-
formation of dipeptidic segments in the full length sp9
molecule was analyzed using the distances between 1H
nuclei of adjacent residues, namely HN and Hα of residue
i and HN of residue i+1 (dNN(i, i+1), dαN(i, i+1)) (22). The
distances d which strictly correlate with signal intensities I
(I ~1/d6) were obtained by transferring the intensities of
the respective NOE signals into interproton distances
using the Bruker program AURELIA. Only unambiguous
signals were used for this analysis. For a few signals that
were weakened by the pre-saturation of the water reso-
nance a correction was applied (-1.5 Å when within 0.005
ppm of the water signal, -1 Å when within 0.025 ppm, and
-0.5 Å when within 0.05 ppm), and a similar correction
was made in cases where two or more signals could not be
resolved individually due to close signal overlap. An equa-
tion given by Bradley et al. [23] was then used to calculate
probabilities for helical or extended conformations.
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